Gyre Therapeutics (NASDAQ:GYRE) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Gyre Therapeutics (NASDAQ:GYRE) from a hold rating to a strong sell rating in a research note released on Monday morning,Zacks.com reports.

A number of other analysts have also commented on GYRE. Wall Street Zen lowered Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Stock Down 8.4%

Gyre Therapeutics stock opened at $7.01 on Monday. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $11.78. The firm’s fifty day moving average is $7.96 and its 200 day moving average is $7.77. The company has a market capitalization of $679.69 million, a PE ratio of 701.70 and a beta of 1.97.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a return on equity of 10.85% and a net margin of 4.31%.The company had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in shares of Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after buying an additional 5,135 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after acquiring an additional 45,772 shares during the period. State Street Corp raised its position in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after acquiring an additional 19,472 shares during the period. Wells Fargo & Company MN boosted its stake in Gyre Therapeutics by 132.4% in the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after acquiring an additional 7,361 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Gyre Therapeutics during the 4th quarter valued at approximately $77,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.